RVBA-ASTRAPharma Manufacturing

AstraZeneca — in detail

Full extracted data, every event in the company's history we've captured, and (soon) external news. The full ratios diagnostic with peer benchmarks lives at /ratios.

Reference sources (3/5)

Source documents
Recent disclosure
Multi-year metrics
Targets
Certifications

External news· 5 ESG-tagged · GDELT

tagged categories: climate · governance · controversy · M&A · regulatory

Source: GDELT 2.0 DOC API · ESG-keyword filtered · 3-month trailing window.

Data by year· every metric + key events per year

Each year shows the firm's reported metrics on the left and the most material events on the right. Up to 10 events per year; the full event log is one click further.

2025

integrated report ↗

P&L highlights (USD)

Headcount (FTE)	2,023people
Revenue	58.7B
Cost of revenue	(10.6B)
Gross profit	48.1B
Operating expenses (S&M + G&A)	(34.4B)
Operating income	13.7B
Net income	10.3B

Balance sheet highlights (USD)

Property, plant & equipment	14.7B
Total assets	114.1B
Total debt	27.9B
Cash & equivalents	5.7B
Minority interest	52M

Market & shares

Market cap (FY-end)	272B
Shares outstanding	1.6B

Events 2025· 5

External assurance referenced

GRI 2-5 references external assurance disclosed in Annual Report 2025 pp. 83, 85, 220-221. Specific assurance level not detailed in this index.

▾ expand

Double materiality assessment updated in 2025

AstraZeneca updated its 2024 double materiality assessment in 2025; the list of material topics in the GRI index reflects this update.

▾ expand

Restatements of information disclosed

GRI 2-4 indicates restatements of information are documented in Annual Report 2025 p. 43 and Sustainability Data Reporting Criteria 2025 p. 34. Specific restatements not detailed in this index document.

▾ expand

Near-zero GWP respiratory inhaler propellant from 2025

AstraZeneca developing next-generation respiratory inhaler propellant with near-zero global warming potential (99.9% lower than today's medicines). First launches anticipated from 2025 subject to regulatory approvals.

▾ expand

Sustainability Data Content Index 2025 - index document only

This document is a SASB and GRI content index that points to the AstraZeneca Annual Report 2025 and Sustainability Data Annex 2025 for actual metric values. No numeric metrics are disclosed in this index document itself.

▾ expand

2024

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	78
Scope 2 (market-based)	—
Gross carbon footprint	—
Net carbon footprint	—

Energy (kWh)

Renewable electricity %

97%

Nature

water withdrawal m3	23% reduction vs 2015
waste generated t	13% reduction vs 2015

Social

community investment amount

126.7MUSD

Circularity

packaging recyclable pct

96%

P&L highlights (USD)

Headcount (FTE)	2,022people
Revenue	54.1B
Cost of revenue	(10.2B)
Gross profit	43.9B
Operating expenses (S&M + G&A)	(33.9B)
Operating income	10B
Net income	7B

Balance sheet highlights (USD)

Property, plant & equipment	11.6B
Total assets	104B
Total debt	28.7B
Cash & equivalents	5.5B
Minority interest	85M

Market & shares

Market cap (FY-end)	201.5B
Shares outstanding	1.6B

Events 2024· 16

Primary: Next-generation propellant for pMDI inhalers (F-gas elimination)

Transitioning pressurised Metered Dose Inhalers (pMDIs) to a next-generation propellant with near-zero Global Warming Potential. First approval received in UK in May 2025 (Trixeo Aerosphere); filings in EU and China; aim to transition wider pMDI portfolio by 2030. At Dunkirk, France, F-gas emissions from manufacturing are eliminated via vacuum purging of empty canisters and cryogenic capture/liquefaction for incineration or recycling. Use-of-sold inhaler propellants are a material part of AstraZeneca's product-emissions footprint.

▾ expand

Primary: Circular operations and waste reduction

Total waste reduced 13% vs 2015. At Coppell, Texas, a circularity programme repurposes ~11,915 metric tons/year of filtered material from a high-volume sachet production process into concrete-industry feedstock to avoid landfill. 96% of paper-based product packaging materials used in 2024 came from sustainable sources. Lab waste reductions through Green Labs programme (lab plastics, gloves recycling; reduced solvent use).

▾ expand

Dependent: Supplier engagement via SBTi and Energize

More than 1,000 suppliers have committed to setting science-based targets — around one in 10 of all companies signed up to SBTi are AstraZeneca partners. Suppliers are supported through innovative decarbonisation solutions including the Energize programme. SMI-led joint China renewable PPA enabled 9 suppliers to procure ~225 GWh/year of wind and solar, with sector-wide annual savings of ~250,000 tCO2e.

▾ expand

100% renewable electricity at sites worldwide by 2025

By 2025 AstraZeneca aims to have 100% renewable electricity consumption at sites worldwide and 100% electric road fleet where technically feasible, reduce total energy consumption from sites by 10% from 2015, and double energy productivity at sites from 2015.

▾ expand

$5M/year for nature restoration & water stewardship

Starting in 2024, AstraZeneca is investing $5 million per year to fund nature restoration and water stewardship projects to address shared water challenges in operating communities.

▾ expand

Ambition Zero Carbon: 90% reduction by 2045, halve value chain by 2030

AstraZeneca aims to halve its entire value chain footprint by 2030 and reduce absolute Scope 3 GHG emissions by 90% vs 2019 baseline by 2045 to become science-based net zero, in alignment with the SBTi Corporate Net-Zero Standard. Investing more than $1 billion to support transition.

▾ expand

Primary: Fleet electrification

63% of AstraZeneca's car fleet are battery electric vehicles as of 2024, with a target of 100% electric road fleet where technically feasible by 2025.

▾ expand

Primary: R&D and manufacturing site decarbonisation (Scope 1 & 2)

Scope 1+2 emissions reduced 77.5% vs 2015 while doubling the business. Largest site Södertälje, Sweden (40% of global production volume) delivered a 98% Scope 1+2 reduction vs 2015 baseline 18 months ahead of its 2026 target; all Swedish sites including Gothenburg R&D have hit the 98% milestone. Newest sites designed to Ambition Zero Carbon Scope 1+2 targets from day one (e.g. DISC, Cambridge).

▾ expand

AZ Forest: 200 million trees, 100,000+ hectares across six continents by 2030

$400 million invested in AZ Forest, a global reforestation and biodiversity programme co-designed with ecological experts, indigenous peoples and local communities. Over 40 million trees planted across six continents since 2020. Projects use diverse, locally appropriate native species; local tree projects monitored for an average of three years and large-scale reforestation projects for at least 10 years. Removals are framed as nature-based; the report does not discuss durable engineered removals (DAC/BECCS). A pilot carbon capture component is featured at the Future Biogas Moor Bioenergy biomethane plant in the UK.

▾ expand

SDG 3.4 alignment via Young Health Programme

Young Health Programme is aligned to the United Nations' Sustainable Development Goal 3.4, which aims to prevent the most common NCDs such as cancer, diabetes, heart disease, and respiratory disease.

▾ expand

see 6 more events →

2023

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	180,898
Scope 2 (market-based)	19,940
Scope 3	6.7M
Cat 1 · Purchased goods	4.6M
Cat 2 · Capital goods	81,938
Cat 3 · Fuel + energy	52,634
Cat 4 · Upstream transport	241,422
Cat 5 · Waste in operations	19,043
Cat 6 · Business travel	155,443
Cat 7 · Employee commuting	50,827
Cat 8 · Upstream leased	30,101
Cat 9 · Downstream transport	135,689
Cat 10 · Processing of sold	0
Cat 11 · Use of sold products	1.3M
Cat 12 · End-of-life	14,579
Cat 13 · Downstream leased	2,101
Cat 14 · Franchises	0
Cat 15 · Investments	0
Gross carbon footprint	6.9M
Net carbon footprint	6.9M

Energy (kWh)

Total energy	1.5B
Renewable energy	(802.7M)
Non-renewable / hydrocarbon	708.7M
Renewable electricity %	95%

Nature

waste generated t	26,213tonnes
waste landfill t	1,136tonnes
water withdrawal m3	3.6Mm³
waste hazardous t	9,661tonnes
waste recycled t	10,941tonnes

Social

community investment amount	115.4MUSD
workforce female pct	54%
employee turnover pct	13%
workforce board female pct	46%
h s total recordable injury rate	1per 1000000 hours
supply chain audited pctⓘ	70%
ethnicity minority pct	37%
h s fatalities	0count
workforce management female pct	47%
h s lost time injury rate	0per 1000000 hours
training hours per employee	18hours

Governance

esg linked executive pay yn	1boolean
audit assurance climate levelⓘ	1scale 0-2

P&L highlights (USD)

Headcount (FTE)	89,900people
Revenue	45.8B
Cost of revenue	(8.3B)
Gross profit	37.5B
Operating expenses (S&M + G&A)	(29.4B)
Operating income	8.2B
Net income	6B

Balance sheet highlights (USD)

Property, plant & equipment	10.5B
Total assets	101.1B
Total debt	27.5B
Cash & equivalents	5.8B
Minority interest	23M

Market & shares

Market cap (FY-end)	207.4B
Shares outstanding	1.6B

Events 2023· 31

Dependent: Supplier decarbonisation — Energize, Activate and SMI Task Force

Founding member of Energize (Schneider Electric + 19 pharma firms enabling supplier PPAs — 286 AZ suppliers registered; 2 TWh first PPA cohort announced Nov 2022). Joined Activate Programme for API supply-chain decarbonisation. SMI Health Systems Task Force signed industry-first renewable power agreement in China (Jan 2024) saving ~120 kt CO2e/yr. Target: 95% of purchased-goods/capital-goods supplier spend with verified SBTs by 2025 (29% in 2023).

▾ expand

Clean heat partnerships + renewable power coalitions across US/UK/China

AstraZeneca is expanding renewable energy access through innovative partnerships: in the US with Vanguard Renewables to transform food/farm waste into renewable natural gas (RNG) supplying all US R&D and manufacturing sites by 2026; in the UK with Future Biogas establishing the first unsubsidised industrial-scale biomethane supply for Macclesfield, Cambridge, Luton and Speke sites; and in China with China Resources Gas, plus a multi-party agreement with Envision Energy targeting ~120,000 tCO2e annual savings. Founding member of 'Energize' coalition with Schneider Electric and 19 healthcare companies, with 286 AZ suppliers registered to buy 2TWh of renewable electricity since 2022.

▾ expand

Primary: Fleet electrification

35% of AstraZeneca's road fleet are battery electric vehicles (vs 2015 baseline). Continued shift away from internal combustion supports Scope 1 reductions.

▾ expand

Primary: Green Labs energy/waste efficiency

Green Labs programme integrates sustainability standards into research processes with 4,000+ colleagues optimising lab practices. Focus on cold storage management, switching off equipment, eco-friendly waste disposal, recycling of plastics/gloves, and reducing raw material/solvent use. 100+ labs certified by My Green Lab; 41 at the highest Green level.

▾ expand

Primary: Battery electric vehicle road fleet by end-2025

EV100 commitment: 100% electric road fleet where technically possible by end of 2025. BEVs reached 35% of fleet in 2023 (up from 10% in 2022, 2% in 2021). Hybrid + PHEV represent additional 40%. Road fleet Scope 1 emissions fell from 92.5 ktCO2e (2015) to 47.8 ktCO2e (2023).

▾ expand

Dependent: Supplier SBT engagement (Scope 3)

With 97% of emissions in Scope 3, AstraZeneca targets 95% of key suppliers/partners by spend to have science-based targets by end of 2025. AZ suppliers represent 12% of all companies taking action with SBTi (as of May 2024). Collaborating via 'Energize' (renewable power access) and 'Activate' (API supply chain decarbonisation) industry programmes.

▾ expand

Primary: Next-generation pMDI inhaler with near-zero-GWP propellant (HFO-1234ze(E))

Tackles ~20% of Scope 3 footprint (Cat 11 use of sold products). Developing pMDI with HFO-1234ze(E) propellant (near-zero GWP) to replace high-GWP HFC propellants currently used in respiratory inhalers. 2023 milestones: Phase III investment decisions, harmonised global development programme, pivotal study readouts, regulatory filing studies initiated. Launch targeted by 2025.

▾ expand

Primary: Business travel emissions management

Cat 6 business travel emissions rose to 155 ktCO2e in 2023 (from 84 kt in 2021 post-COVID rebound) but remain below 2019 baseline of 327 kt. 32% of business-travel supplier spend now covered by verified SBTs (up from 14% in 2022); targeting 50% by 2025.

▾ expand

Dependent: Upstream transport modal shift — Air2Sea&Rail

Reducing Cat 4 upstream transport emissions by shifting from air to sea and rail freight. 73% of tonne.km and 64% of volume moved by sea/rail in 2023. 27% of category-4 supplier spend now covered by verified SBTs (up from 19% in 2022).

▾ expand

Ambition Zero Carbon SBTi-validated targets

Reduce absolute Scope 1 and 2 GHG emissions by 98% by 2026 from 2015 base year; reduce absolute Scope 3 by 50% by 2030 and 90% by 2045 from 2019 base year.

▾ expand

see 21 more events →

2022

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	237,703
Scope 2 (market-based)	18,491
Scope 3	6.2M
Cat 1 · Purchased goods	4.5M
Cat 2 · Capital goods	76,863
Cat 3 · Fuel + energy	57,975
Cat 4 · Upstream transport	218,745
Cat 5 · Waste in operations	18,434
Cat 6 · Business travel	145,814
Cat 7 · Employee commuting	44,128
Cat 8 · Upstream leased	25,872
Cat 9 · Downstream transport	118,800
Cat 11 · Use of sold products	960,650
Cat 12 · End-of-life	13,572
Cat 13 · Downstream leased	6,082
Gross carbon footprint	6.4M
Net carbon footprint	6.4M

Energy (kWh)

Total energy	1.6B
Renewable energy	(712.4M)
Non-renewable / hydrocarbon	856.4M
Renewable electricity %	99%

Nature

water withdrawal m3	3.8Mm3
waste generated t	25,493tonnes
waste recycled t	9,072tonnes
waste landfill t	596tonnes
waste hazardous t	9,719tonnes

Social

workforce female pct	53%
workforce board female pct	39%
ethnicity minority pct	36%
employee turnover pct	19%
community investment amount	108.1MUSD
h s lost time injury rate	0per 1000000 hours
supply chain audited pctⓘ	60%
h s total recordable injury rate	1per 1000000 hours
h s fatalities	0count
workforce management female pct	50%

Governance

audit assurance climate levelⓘ	1level
esg linked executive pay yn	1yes/no

P&L highlights (USD)

Headcount (FTE)	83,500people
Revenue	44.4B
Cost of revenue	(12.4B)
Gross profit	32B
Operating expenses (S&M + G&A)	(28.2B)
Operating income	3.8B
Net income	3.3B

Balance sheet highlights (USD)

Property, plant & equipment	9.4B
Total assets	96.5B
Total debt	28.2B
Cash & equivalents	6.2B
Minority interest	21M

Market & shares

Market cap (FY-end)	210.9B
Shares outstanding	1.5B

Events 2022· 16

CDP A List 2022 (Climate and Water Security)

For the seventh consecutive year, AstraZeneca achieved a double A-rating from CDP for Climate Change and Water Security. CDP Forest score: B for timber, B for palm oil, C for cattle.

▾ expand

Primary: F-gas substitution in inhalers (HFO-1234ze next-gen pMDI)

Targeting 15% of Scope 3 footprint via product innovation. Partnership with Honeywell announced 2022 to develop next-generation pressurised metered-dose inhaler using HFO-1234ze, a near-zero GWP propellant; first launch targeted by 2025. Use-of-sold-products footprint targeted for 95% reduction by 2045. F-gas management programme initiated; reduce and capture F-gas emissions from production of respiratory medicines.

▾ expand

Dependent: Supplier engagement via Energize + CDP Supply Chain

By end 2025, 95% of spend in Scope 3 cat 1 (purchased goods) and cat 2 (capital goods) to be with suppliers having SBTs aligned to <1.5°C (12% achieved in 2022); 50% of spend in cat 4 (upstream transport) and cat 6 (business travel) likewise. Joined Energize (Schneider Electric + 16 pharma sponsors) to give suppliers access to renewable PPAs — 210+ AZ suppliers registered, 54% undertook Scope 3 training. 480+ suppliers (58% of in-scope spend) report GHG via CDP Supply Chain programme.

▾ expand

Dependent: Business travel reduction

Business air travel emissions in 2022 were 53% below the 2019 baseline (baseline of 327 ktCO2e for cat 6 business travel). Combined with freight is included in target of 50% supplier spend by 2025 covering transportation, distribution and business travel having SBTs, and 46% GHG reduction by 2030.

▾ expand

Dependent: Freight modal shift (air to sea/rail)

Achieved 74% by tonne.km transition of freight from air to sea and rail by 2022 — addressing Scope 3 cat 4 (upstream transportation and distribution), which had a 2019 baseline of 248 ktCO2e. Target 46% GHG reduction in upstream transportation and business travel by 2030.

▾ expand

100% renewable electricity (99% in 2022 due to Russia); PPAs + on-site solar PV

AstraZeneca is committed to 100% renewable energy by end of 2025 (RE100). In 2021 it transitioned to 100% imported electricity from certified renewable sources via EACs (same country, same year); this fell to 99% in 2022 as Russia certs were unavailable. Targeting majority of electricity in Sweden, UK, US via new PPAs. Committed $23.1m over 2022-2024 to on-site solar PV at ten sites in eight countries (27 GWh once operational, ~3% of global electricity use). Joined Eurelectric 24/7 taskforce for temporal matching. For heat: UK biomethane partnership with Future Biogas (signed 2021), exploring RNG/biomethane for US sites, electrification via heat pumps and electric boilers.

▾ expand

Primary: EV transition of road fleet (EV100)

Signed EV100 commitment to maximise EV transition by 2025. By 2022: 10% EV, 63% green fleet (EV, hybrid or plug-in hybrid); first market has reached 100% EV. Transition impeded by lack of vehicles, EV infrastructure and supply chain issues in some markets.

▾ expand

Primary: Site energy efficiency and electrification (Scope 1&2)

Natural Resource Efficiency Fund has invested ~$150m since 2015 in environmental efficiency innovations; $26.6m further invested in 2022 across 31 new projects ($21m on energy efficiency and on-site solar PV). 14.4% absolute energy reduction since 2015 baseline; EP100 target to double energy productivity by 2025. Substituting natural gas with renewable heat sources; heat pumps and electric boilers prioritised.

▾ expand

BECCS for Scope 1&2 residuals from 2026; nature-based removals via AZ Forest from 2030

AstraZeneca's compensation hierarchy is Eliminate → Reduce → Substitute → Compensate. Residual Scope 1&2 emissions from 2026 will be compensated through high quality removals using Bioenergy with Carbon Capture and Storage (BECCS). For the 2030 carbon-negative value chain goal, residual emissions will be compensated through high quality nature-based solutions, anchored by the AZ Forest 50-million-tree programme (10.5 million planted since 2020 across Australia, Indonesia, Ghana, US, UK). Aims to remove more CO2e than emitted from 2030 to become carbon negative.

▾ expand

Alexion integration into sustainability programmes

In 2022, Alexion (Rare Disease therapy area) was integrated into Product Sustainability programmes including first LCA studies. Workforce safety reported separately for Alexion (6% of total workforce).

▾ expand

see 6 more events →

2021

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	239,468
Scope 2 (market-based)	21,135
Scope 3	5.9M
Cat 1 · Purchased goods	4.4M
Cat 2 · Capital goods	88,762
Cat 3 · Fuel + energy	51,333
Cat 4 · Upstream transport	228,675
Cat 5 · Waste in operations	19,372
Cat 6 · Business travel	83,774
Cat 7 · Employee commuting	41,293
Cat 8 · Upstream leased	25,074
Cat 9 · Downstream transport	129,078
Cat 11 · Use of sold products	835,337
Cat 12 · End-of-life	20,023
Cat 13 · Downstream leased	2,382
Gross carbon footprint	6.2M
Net carbon footprint	6.2M

Energy (kWh)

Total energy	1.7B
Renewable energy	(711.9M)
Non-renewable / hydrocarbon	955.9M
Renewable electricity %	88%

Nature

waste recycled t	9,701tonnes
water withdrawal m3	3.7Mm³
waste hazardous t	10,031tonnes
waste generated t	27,659tonnes
waste landfill t	906tonnes

Social

workforce management female pct	44%
h s total recordable injury rate	1per 1000000 hours
ethnicity minority pct	32%
community investment amount	112.9MUSD
workforce female pct	48%
h s lost time injury rate	0per 1000000 hours
workforce board female pct	39%
h s fatalities	2count

Governance

audit assurance climate levelⓘ

1level

P&L highlights (USD)

Headcount (FTE)	83,100people
Revenue	37.4B
Cost of revenue	(12.4B)
Gross profit	25B
Operating expenses (S&M + G&A)	(23.9B)
Operating income	1.1B
Net income	112M

Balance sheet highlights (USD)

Property, plant & equipment	10.2B
Total assets	105.4B
Total debt	29.7B
Cash & equivalents	6.3B
Minority interest	19M

Market & shares

Market cap (FY-end)	164.3B
Shares outstanding	1.4B

Events 2021· 18

CDP A List 2021 — Climate Change and Water Security

CDP-worldwide double A rating for climate change and water security for the sixth consecutive year. Also first published CDP Forests rating: C.

▾ expand

Expanded Ambition Zero Carbon: SBTi-verified net zero by 2045

AstraZeneca expanded its Ambition Zero Carbon strategy to include a net zero emissions target across the value chain by 2045, verified by SBTi under their new Corporate Net Zero Standard. One of first seven companies worldwide to have net zero Scope 1-3 targets verified. Also targets 50% Scope 3 reduction by 2030 from 2019 baseline, and 98% Scope 1+2 reduction by 2026 from 2015 baseline.

▾ expand

Acquisition of Alexion

Alexion acquired in 2021. Reporting boundary expanded to include Alexion across all scopes (1, 2, 3) and integrated to previous years' reporting. Affects 2021 data for emissions, water, waste, and workforce metrics.

▾ expand

Reporting boundary expanded to include Alexion

Scope 1, 2 and 3 emissions from Alexion acquired during 2021 - reporting boundary expansion to include the acquired business, calculate emissions across all scopes consistently, and integrate to previous years reporting.

▾ expand

Reports alignment with UN SDGs 3, 5, 6, 7, 8, 12, 13, 15, 17

AstraZeneca evaluates contribution to UN SDGs by connecting them to targets, annual progress, material focus areas. Highlighted SDGs: 3 (Good health), 5 (Gender equality), 6 (Clean water), 7 (Affordable & clean energy), 8 (Decent work), 12 (Responsible consumption), 13 (Climate action), 15 (Life on land), 17 (Partnerships).

▾ expand

AZ Forest — 50 million trees by 2025

AZ Forest commitment to plant and maintain 50 million trees worldwide by end of 2025, partnering with One Tree Planted. 3,430,061 trees planted since 2020. Active in Indonesia (20m), Australia (25m), UK (1m+). Supports WEF 1t.org platform.

▾ expand

Water stewardship pilot at six water-scarce sites

Introduced water stewardship pilot focused on six prioritised sites in water-scarce areas across five countries. Will set locally-appropriate water targets in 2022 and long-term contextual targets by 2025. Supported by WWF Sweden partnership and WWF water risk filter tool.

▾ expand

$1 billion Ambition Zero Carbon programme with EV100, RE100, EP100 targets

Flagship programme commits to 98% Scope 1+2 reduction by 2026 (2015 baseline), 50% Scope 3 by 2030 (2019 baseline), 90% Scope 3 by 2045. First pharma to join all 3 of Climate Group's RE100, EV100, EP100. Targets SBTi-verified.

▾ expand

Supplier diversity programme expansion to 10 countries by 2025

Launched supplier diversity programmes in Australia, New Zealand, Poland in 2021, bringing total to 8 countries (US, Puerto Rico, Brazil, UK, South Africa + 3 new). 20% increase in spend with diverse suppliers in 2021.

▾ expand

Nature-based removals via AZ Forest and future BECCS for residual emissions

Plans to compensate for any residual Scope 1 and 2 emissions through high quality removals using BECCS (bioenergy with carbon capture and storage). The Future Biogas partnership in UK will capture biogenic CO2 from anaerobic digestion of energy crops and put it into permanent storage in UK North Sea rock formations. AZ Forest plants 50 million trees worldwide by 2025 (3.43M planted since 2020) for nature-based sequestration. Target to be carbon negative from 2030 by removing more CO2 from the atmosphere than emitted.

▾ expand

see 8 more events →

2020

sustainability report ↗

Energy (kWh)

Renewable electricity %

89%

Social

workforce management female pct	47%
workforce female pct	51%
workforce board female pct	36%
community investment amount	76MUSD

Governance

audit assurance climate levelⓘ

1level

P&L highlights (USD)

Headcount (FTE)	76,100people
Revenue	26.6B
Cost of revenue	(5.3B)
Gross profit	21.3B
Operating expenses (S&M + G&A)	(16.2B)
Operating income	5.2B
Net income	3.2B

Balance sheet highlights (USD)

Property, plant & equipment	8.9B
Total assets	66.7B
Total debt	19.7B
Cash & equivalents	7.8B
Minority interest	16M

Market & shares

Market cap (FY-end)	132.5B
Shares outstanding	1.3B

Events 2020· 17

Primary: Downstream transportation and distribution

Downstream transportation accounts for 4.8% of Scope 3. Achieved 29% reduction in freight and logistics emissions since 2015. Monitoring 1,300+ global logistics routes.

▾ expand

Dependent: Use of sold products (patient pMDI use)

Use of sold products (primarily pMDI patient use) accounts for 12.5% of Scope 3. Addressed via next-generation low-GWP inhalers and research showing improved asthma management reduces reliever overuse — up to 250,000 tonnes CO2e per year in UK alone tied to reliever overuse.

▾ expand

Primary: Fuel combustion / clean heat decarbonisation

Fuel combustion is 54.5% of Scope 1+2 — the largest operational source. Joined Renewable Thermal Collaborative in 2020. Clean heat studies underway for UK and US portfolios considering green gas to electrification of heat. Doubling energy productivity by 2025 under EP100.

▾ expand

Primary: 100% electric vehicle fleet by 2025 (EV100)

Fleet accounts for 17% of Scope 1+2 emissions. Committed to EV100 — switch to fully electric vehicle fleet by 2025. EV readiness study completed for all markets with fleet presence; countries identified as 'EV ready'.

▾ expand

Primary: Eliminate F-Gas emissions at sites + next-generation low-GWP inhalers

Site F-Gas and solvents account for 19.2% of Scope 1+2. Pressurised metered-dose inhalers (pMDIs) use HFC propellants subject to Kigali Amendment phase-down. AstraZeneca committed to launch next-generation inhaler with near-zero GWP propellant by 2025 (90-99% reduction).

▾ expand

AZ Forest - 50 million trees nature-based removals by 2025

AZ Forest is a global reforestation initiative to plant 50 million trees worldwide by 2025 as the primary nature-based solution to address residual emissions on the path to carbon negative value chain by 2030. More than 337,000 trees planted in Indonesia and Australia in 2020. Trees naturally remove CO2 while supporting disease prevention and biodiversity. AstraZeneca commits to no reliance on offset schemes for its 2025 operations target.

▾ expand

Next-generation low-GWP inhaler by 2025

Committed to launch next-generation pMDI inhaler with near-zero GWP propellant by 2025 (90-99% lower GWP).

▾ expand

Founding member of Circular Bioeconomy Alliance

Co-authored 10-point action plan for the circular bioeconomy. Eliminating 70 million single-use plastic items per year from a respiratory therapy device.

▾ expand

Aligned to SDGs 3, 5, 8, 12, 13, 17

Reports primary contribution to UN SDGs 3 (Good health), 5 (Gender equality), 8 (Decent work), 12 (Responsible consumption), 13 (Climate action), 17 (Partnership for goals).

▾ expand

Launched Ambition Zero Carbon strategy

Committed to zero carbon operations (sites and fleet) by 2025 without carbon credits, and carbon negative across entire value chain by 2030. $1 billion programme. Targets exceed SBTi 1.5°C pathway.

▾ expand

see 7 more events →